T he clustering of cardiovascular risk factors associated with the metabolic syndrome and type 2 diabetes suggests central mechanisms may exist that account for the presence of these abnormalities. Likewise, this clustering also suggests that key therapeutic targets may exist that could allow improvements in many of these parameters. Extensive data implicate peroxisome proliferator-activated receptor-alpha (PPARα) as an important transcriptional regulator of lipid metabolism, energy balance and inflammation. PPARα is also an established drug target. Experimental data show that activation of PPARα by agonists such as fenofibrate improves dyslipidaemia, increases cholesterol efflux and limits inflammation. All of these effects would also be predicted to decrease atherosclerotic risk. Evidence from surrogate markers in humans is also supportive of the concept that PPARα may act as a central target capable of influencing a variety of different pathways involved in lipid metabolism. Thus, fenofibrate offers the potential for inducing a co-ordinated PPARα response that may improve dyslipidaemia, repress inflammation and limit atherosclerosis in patients with the metabolic syndrome or type 2 diabetes. Diabetes Vasc Dis Res 2007;4(suppl 3):S12-S14
Introduction
The clustering of cardiovascular risk factors associated with the metabolic syndrome suggests central mechanisms may exist that may help explain why these abnormalities often arise in the same patient. Evidence from basic science studies suggests that peroxisome proliferator-activated receptoralpha (PPARα), a critical transcriptional regulator of lipid metabolism and inflammation, might be just such a target.
PPARs, members of the nuclear receptor family, are ligandactivated transcription factors. PPARα activation is initiated by binding of an agonist such as fenofibrate to the ligand-binding domain of the nuclear receptor. This allows PPARα heterodimerisation with the retinoid X receptor (RXR), another nuclear receptor, which is required for transcriptional PPARα activity. This PPARα-RXR complex subsequently recognises and binds to specific PPARα response elements in the promoter regions of target genes, allowing the expression of those genes to be regulated. PPARs can both induce and repress gene expression. In the case of PPARα, these target genes tend to be ones involved in lipoprotein and fatty acid metabolism, cholesterol homeostasis and inflammation. 1 Through their action in the nucleus, PPARα can regulate the expression of multiple gene cassettes, thus offering the opportunity for an integrated, co-ordinated response across different organs and cells in response to a specific upstream signal (figure 1).
Impact of PPARα on lipid metabolism
PPARα plays an important role in regulating the oxidation of fatty acids. Consistent with this, PPARα is expressed primar- ily in metabolically active, energy-requiring tissues such as the liver, heart, skeletal muscle and kidney. PPARα target genes include a number of proteins essential for fatty acid uptake, intracellular transport and fatty acid β-oxidation. Activation of PPARα, as can occur in response to fenofibrate, induces expression of lipoprotein lipase, leading to increased triglyceride hydrolysis and consequent lowering of very-low density lipoproteins (VLDL). In addition, activation of PPARα represses the expression of apolipoprotein C-III (apoC-III), which is an inhibitor of lipoprotein lipase. PPARα activation also increases the transcription of the main high-density lipoprotein (HDL) apolipoproteins apoA-I and apoA-II. Given these biological effects, the clinical response to fenofibrate -a reduction in triglycerides and elevation of HDLcan be seen as a direct consequence of PPARα activation. Data for surrogate markers in humans are supportive of the concept that PPARα may act as a central target that can influence a variety of different pathways involved in lipid metabolism. 1 
Impact of PPARα on inflammation and atherosclerosis
There is also evidence to support a role for PPARα in the regulation of vascular function and inflammation. PPARα activation may influence the development of atherosclerosis via indirect effects on metabolism in adipose tissue, skeletal muscle and the liver. Alternatively, evidence of the effects of PPARα activation in endothelial cells, vascular smooth muscle cells and inflammatory cells such as macrophages and T lymphocytes suggests that PPARα may also directly modulate responses in the vasculature (figure 2). 2 Considerable basic science evidence supports an antiatherosclerotic, anti-inflammatory action of PPARα activation, as shown by increases in apoA-I and ABCA1, and decreases in endothelin 1, tissue factor and vascular cell adhesion molecule-1 (VCAM-1). 3 In particular, VCAM-1 plays a critical role in the development of atherosclerosis as it allows for adhesion of monocytes to the endothelium, thereby initiating a cascade of events which leads to the development of atherosclerotic plaque. Experimental studies have shown that treatment with fenofibrate represses VCAM-1 expression in a PPARα-dependent manner. In endothelial cells isolated from mice that are genetically lacking PPARα, the effect of PPARα ligands on VCAM-1 expression is abolished. Interestingly, endothelial cells lacking PPARα already have induced VCAM-1 levels. Together, these data suggest that PPARα functions as a 'brake' on inflammation. 4 Cytokines such as tumour necrosis factor-alpha (TNFα), interleukins and interferon-γ, which are released from T lymphocytes, play a critical role in the inflammatory process associated with atherogenesis and atherosclerosis. These cytokines are thought to contribute to the development of plaque via activation of endothelial cells and modulation of macrophage and vascular smooth muscle cell responses. Treatment with fenofibrate can repress the release of these cytokines in a concentration-dependent manner. 5 As the release of these cytokines is a very early signal in atherogenesis, repression of inflammation by decreasing cytokine release could be very important in modulating the cascade of responses in atherosclerosis. Thus, these data implicate PPARα as a potential nodal point for the regulation of T-cellmediated inflammatory responses. Findings suggest that PPARα may repress inflammatory target genes indirectly by altering the expression of the master transcription factor nuclear factor kappa B (NF-κB). 2 There is also evidence to show that pro-inflammatory cytokines such as TNFα play a role in the development of non-alcoholic fatty liver disease (NAFLD), which is associated with insulin-resistant states. Accumulation of fat in the liver, resulting from elevated levels of triglycerides, leads to an increase in pro-inflammatory cytokines such as TNFα and a decrease in hormones such as adiponectin that are thought to be anti-inflammatory ( figure 3 ). Cytokine imbalance associated with the metabolic syndrome is thought to be the mechanism driving the development of NAFLD. Mice which lack the gene for the TNFα receptor do not develop NAFLD, which supports the hypothesis that modulation of TNFα can prevent development of this condition, as well as diabetes. 6 Recent work has also raised the possibility that more 'inflammatory' forms of HDL may exist, enriched for example in components such as serum amyloid A (SAA), in contrast to more typical anti-inflammatory HDL elements such as paraoxanase 1 or even apoA1. Inflammatory cytokines such as TNFα and certain interleukins regulate these HDL components in a co-ordinated way that would promote inflammation and decrease the anti-atherosclerotic effects of HDL. 1 Recent work suggests that PPARα agonists such as fenofibrate can block these cytokine-induced changes in HDL, though not in the absence of PPARα. 7 
Conclusion
Experimental evidence supports the mechanistic view that PPARα may be a central target regulating fatty acid oxidation, lipid metabolism and inflammatory and vascular responses. Most of the available in vitro and experimental data support PPARα activation in improving dyslipidaemia, increasing cholesterol efflux and reducing inflammation; all of these effects would be predicted to decrease atherosclerosis. Similarly, PPARα activation may have a role in preventing or limiting the development of NAFLD, which is commonly associated with metabolic syndrome and type 2 diabetes. Fibrates that are PPARα agonists, such as fenofibrate, offer the possibility of co-ordinated modification to repress inflammatory mechanisms and limit the development of atherosclerosis in individuals with insulin-resistant conditions.
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